Scharrer I - Search Results

1

Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS.

Lalezari S, Martinowitz U, Windyga J, Enriquez MM, Delesen H, Schwartz L, Scharrer I. Lalezari S, et al. Among authors: scharrer i. Haemophilia. 2014 Jan;20(1):e15-22. doi: 10.1111/hae.12294. Epub 2013 Nov 20. Haemophilia. 2014. PMID: 24252058 Free PMC article. Clinical Trial.

2

Efficacy of a sucrose-formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A.

Scharrer I, Brackmann HH, Sultan Y, Abshire T, Gazengel C, Ragni M, Gorina E, Vosburgh E, Kellermann E. Scharrer I, et al. Haemophilia. 2000 Nov;6(6):614-8. doi: 10.1046/j.1365-2516.2000.00432.x. Haemophilia. 2000. PMID: 11122384 Clinical Trial.

3

Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany.

Auerswald G, von Depka Prondzinski M, Ehlken B, Kreuz W, Kurnik K, Lenk H, Scharrer I, Schramm W, Zimmermann R. Auerswald G, et al. Among authors: scharrer i. Haemophilia. 2004 Sep;10(5):499-508. doi: 10.1111/j.1365-2516.2004.00950.x. Haemophilia. 2004. PMID: 15357777

4

European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients.

Rothschild C, Scharrer I, Brackmann HH, Stieltjes N, Vicariot M, Torchet MF, Effenberger W. Rothschild C, et al. Among authors: scharrer i. Haemophilia. 2002 Mar;8 Suppl 2:10-4. doi: 10.1046/j.1351-8216.2001.00131.x. Haemophilia. 2002. PMID: 11966846 Clinical Trial.

5

Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates.

Scharrer I, Bray GL, Neutzling O. Scharrer I, et al. Haemophilia. 1999 May;5(3):145-54. doi: 10.1046/j.1365-2516.1999.00300.x. Haemophilia. 1999. PMID: 10444280 Review.

6

Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients.

Borel-Derlon A, Federici AB, Roussel-Robert V, Goudemand J, Lee CA, Scharrer I, Rothschild C, Berntorp E, Henriet C, Tellier Z, Bridey F, Mannucci PM. Borel-Derlon A, et al. Among authors: scharrer i. J Thromb Haemost. 2007 Jun;5(6):1115-24. doi: 10.1111/j.1538-7836.2007.02562.x. J Thromb Haemost. 2007. PMID: 17403090 Free article. Clinical Trial.

7

Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII.

Scharrer I, Ehrlich HJ. Scharrer I, et al. Haemophilia. 2001 Jul;7(4):346-8. doi: 10.1046/j.1365-2516.2001.00515.x. Haemophilia. 2001. PMID: 11442637 Review.

8

Increased frequency of the CTLA-4 49 A/G polymorphism in patients with acquired haemophilia A compared to healthy controls.

Pavlova A, Diaz-Lacava A, Zeitler H, Satoguina J, Niemann B, Krause M, Scharrer I, Hoerauf A, Wienker T, Oldenburg J. Pavlova A, et al. Among authors: scharrer i. Haemophilia. 2008 Mar;14(2):355-60. doi: 10.1111/j.1365-2516.2007.01618.x. Epub 2007 Dec 10. Haemophilia. 2008. PMID: 18081831

9

HLA genotype in patients with acquired haemophilia A.

Pavlova A, Zeitler H, Scharrer I, Brackmann HH, Oldenburg J. Pavlova A, et al. Among authors: scharrer i. Haemophilia. 2010 May;16(102):107-12. doi: 10.1111/j.1365-2516.2008.01976.x. Haemophilia. 2010. PMID: 20536993

10

Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.

Scharrer I. Scharrer I. Haemophilia. 1999 Jul;5(4):253-9. doi: 10.1046/j.1365-2516.1999.00319.x. Haemophilia. 1999. PMID: 10469179 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

238 results

Search Page